Ventricular Tachycardia Ablation Research Articles

Role of mechanical circulatory support in VT ablation procedures: data from the German PROTECT VT registry

Abstract Introduction Ventricular tachycardia (VT) ablation in patients with progressed heart failure (HF) is known to be complex and associated with a high periprocedural risk and mortality, in part due due to hemodynamic instability during ongoingVTs. Use of mechanical circulatory support (MCS) systems has been already implemented in complex high-risk percutaneous coronary intervention (CHIP-PCI) workflows. Use and benefit of MCS in VT ablation is still under debate. MCS protected VT ablation (proVT-A) might be associated with improved clinical outcomebut potentially comes along with an increased risk of periprocedural complications. Based on data of four German high-volume centers we aimed to analyze retrospective data on patient characteristics and impact of proVT-A with respect to safety and mid-term efficacy. Methods All patients undergoing proVT-A as a primary approach from four German EP centers were included in the analysis. Use of MCS in bailout scenariosin VT ablation were not included. Patient characteristics, procedural parameters and clinical outcome were evaluated. The primary endpoint was a combined endpoint of VT/VF recurrence and all-cause death. Results 41 patients who underwent proVT-A were included. Mean age was 64±11a, 92% of patients were male (38/41), 65% (27/41) suffered from ischemic cardiomyopathy, mean left ventricular ejection fraction was 33±13%,76% (31/41) of patients presented with a documented hemodynamically not tolerated VT, mean PAAIN-ESD score was 13±7, and 46% (19/41) had a history of a previous VT ablation w/o MCS. During proVT-A procedure at least one VT was inducible and mappable in 35 patients (85%). Acute procedural success was 85%, with only n=6 patients remaining inducible for VT. Mean procedure duration was 245±46min. With respect to periprocedural safety (30days)a total of n=12 relevant procedural complications were reported in 8 patients. This included n=5 vascular access complications, of which n=3 requiring transfusion or surgery. One case of periprocedural death was reported 6h post proVT-A due to PEA. Three patients developed pericardial effusion, one requiring drainage. Freedom from VT/VF was 78% (n=9 VT/VF recurrences) after a mean follow-up (FU) of 15±14 months (figure 1A). Death of any cause occurred in n=9 patients (figure 1B). In summary, after a mean FU of 15±14 months n=16 patients (39%) met the combined endpoint of VT/VF recurrence and all-cause death (figure 1C). Conclusion Patients enrolled in the German PROTECT VT Registry had significant cardiovascular comorbidities and therefore represent a high-risk population for VT ablation. Use of MCS was feasible, comparably safe, associated with high procedural and promising long-term success rate. These results highlight the need for larger registries and future prospective trials evaluating the potential benefit of proVT-A in selected patients. Further, it should be aimed for optimization of periprocedural vascular access site management.

Ventricular tachycardia mapping and ablation using MIXture of well-established approaches. The MIX-VT study

Abstract Introduction Ablation for ventricular tachycardia (VT) is still challenging despite impressive technology development, especially in mid- or low-volume centers. The most frequently used approach is homogenization of scar area responsible for VT, combined with standard electrophysiological (EP) approaches such as VT inducibility and mapping. However, in real life long-term efficacy of VT ablation in such centers does not exceed 50%. We hypothesized that an approach consisting of the mixture of various well-established parameters would be more effective than scar homogenization and VT non-inducibility as the endpoints. Purpose To compare the outcome of VT ablation using the standard approach (scar homogenization) and a more complex approach, called the MIX-VT protocol, using late potential mapping + pace mapping with rapid change of VT morphology to localize the critical isthmus + core isolation. All procedures were performed using the 3D mapping system, Pentaray mapping catheter, Smart-Touch ablation catheter and intracardiac echocardiography (ICE). Methods 48 consecutive patients (41 male, mean age 71.5 years) with ischemic cardiopathy referred for urgent VT ablation were included: 23 patients underwent "standard" VT ablation between December 2018 and December 2019, whereas the next 25 patients underwent ablation using the MIX-VT protocol between January 2020 and December 2020. First step in the MIX-VT group was to perform ICE imaging of the scar area from the right ventricle. Next, left ventricular maps were created during rhythm at which spontaneous VT occurred (sinus or paced). Areas of late potentials were identified to localize the critical isthmus where the abrupt change in the paced-QRS axis was seen. Finally, areas delineated by these two above-mentioned maneuvers where ablated in order to achieve core isolation (Figure 1). The patients were followed for 12 months in the outpatient clinic during ICD examination. The composite end-point for follow-up was VT recurrences terminated by anty-tachycardia pacing (ATP) or shock, or death. Results Clinical and demographic variables were similar between the two groups (Figure 2), except for a higher prevalence of diabetes mellites and number of previous ablations in the standard group (4/25 [16%] vs 10/23 [43%], p=0.03 and 2/24 vs 8/23 [34.8], p=0.03, respectively). Three patients from the MixVT group and one patient from the standard group were lost to follow-up. During follow-up, VT recurrences were significantly less frequent in the MIX-VT group (3/22 [13.6] vs 10/22 [45.4]. p=0.02. It was mostly driven by less ATP therapy. (Figure 2). One patient from the standard approach groups died. Conclusion Ablation for VT in low- or medium volume centers using the combination of well-established various EP approaches resulted in the improvement in overall survival and arrythmia-free survival. The presented approach does not involve additional resource utilization.

Scar tissue characterization to predict arrhythmia recurrence in patients undergoing ventricular tachycardia ablation: cardiac computed tomography compared with cardiac magnetic resonance

Abstract Background The role of imaging in evaluating patients undergoing ventricular tachycardia (VT) ablation is crucial for planning, procedural success, and clinical outcomes. In daily practice, cardiac computed tomography (CCT) assessing wall thinning and late iodine uptake (LI) and cardiac magnetic resonance (CMR) assessing late-gadolinium enhancement (LGE) are most commonly implemented. However, data comparing the two imaging modalities for scar tissue characterization is scarce. Aims To compare the performance of both imaging modalities for scar tissue characterization in ischemic (ICM) and non-ischemic (NICM) patients undergoing VT ablation and predict procedural outcomes. Methods In a retrospective analysis, consecutive patients undergoing both CCT and LGE-CMR before scheduled VT ablation were included. The presence and extent of scar was assessed by means of each imaging modality using dedicated softwares (MUSIC and ADAS). To compare scar distribution and agreement between the two modalities, a scar classification scheme was used for all 17 AHA segments: 0 points (no scar present), 1 point (scar <50% of total segment area), 2 points (scar representing 50-99% of total segment area) or 3 points (scar present in 100% of the segment area).<scar<100%)><scar<100%> Results 36 patients (67±10 years; 97% male; LVEF 39±10%; 72% ischemic) undergoing CCT and LGE-CMR before scheduled VT ablation were included. In the ICM group, mean detected scar burden was higher than in the NICM group on LGE-CMR (total volume: 62.3±32.9g vs. 32.8±9.5g, p<0.001), using wall thinning model (WT)(mean scar area 69.0±45.6 cm2 vs. 23.4±23.6cm2, p=0.005) as well as LI (dense scar area: 39.2±28.1 cm2 vs. 11.0±6.3 cm2 , p=0.005). The absolute score difference per segment and patient between CCT and LGE-CMR was calculated and summed for all patients divided by the number of patients. Differences were more pronounced for NICM compared to ICM and LGE-CMR showed better concordance to LI than WT in both NICMP and ICM (Figure). Total procedure time was 205±68 min (ablation time 28±16 min; fluoroscopy time 15 ± 12 min). During a follow-up period of 19±7 months, 87 sustained VT episodes in 12 patients (33%) were documented. Three patients (8%) underwent a second VT ablation and one patient (3%) died during follow-up. In ICM, total scar volume on LGE-CMR and scar area on LI showed numerically higher predictive value for VT recurrence than total scar area by means of WT (AUC: LGE 0.76, LI 0.78 and WT 0.65 respectively), while in NICM scar characterization by means of WT yielded higher performance to predict VT recurrence than LI or LGE-CMR (AUC: LGE 0.67, LI 0.58, WT 0.83 respectively). Conclusions In patients undergoing VT ablation, both LGE-CMR and CCT are valuable for scar tissue characterization. Late iodine uptake on CCT showed a high concordance with LGE-CMR in both NICM and ICM.</scar<100%></scar<100%)>

Exploration of peak frequency mapping for ventricular tachycardia ablation. Identification of critical isthmus zones during substrate mapping

Abstract Background/Introduction The ability to classify and differentiate between near field and far-field components of intracardiac signals is a key element in identifying critical arrhythmogenic substrate during ventricular tachycardia (VT) ablation. Near Field algorithms based on omnipolar electrograms enable detection and automation of true localised signals providing unique insights into substrate characteristics. This novel feature identifies localised signal peak frequency (PF) which can be displayed across different voltage ranges. Purpose/Aims The significance of PF mapping in the context of VT ablation is limited and its utility in the identification of the critical diastolic isthmus zone (IZ) is not known. The aim of this study is to explore the utilisation of PF mapping during VT ablation and evaluate whether significant differences in PF occur within areas of interest and critical components of the VT circuit during substrate mapping. Methods All patients underwent VT ablation using the EnSite™ X mapping system with the HDGrid omnipolar mapping catheter. Only cases with both high density sinus rhythm (SR) substrate maps and VT activation maps with clear identification of the IZ were included. VT activation and propagation maps were generated and the diastolic IZ was superimposed onto the SR substrate map. PF analysis was performed retrospectively. Surface area, omnipolar voltage and PF of the maps were measured in the SR substrate maps and co-localised with the critical IZ of the VT circuit as identified in the VT activation maps. Analysis of PF was conducted across different voltage ranges: healthy myocardium (>1.5mV), scar (1.5-0.5mV) and dense scar (0.5-0.1mV). Sensitivity and specificity measurements were made within segments of the IZ and non-isthmus zones and depicted as ROC curves. Results 55 patients underwent VT ablation over a 12-month period, with a total of 18 fulfilling the inclusion criteria. Mean age was 70 (±12.5years) with an average ejection fraction of 36%. The overall PF of the SR substrate maps was 121.85±26.85 Hz, compared to 162.22±46.22Hz within the IZ (p=0.002). Within the low voltage scar region, the overall PF was 120.86±33.24Hz compared to 188.32±81.36Hz within the IZ (p=0.003). No significant difference in PF was observed within healthy myocardium (112.70±52.06 Hz) compared to components of the IZ within the >1.5mV range (157.61±136.11Hz), p=0.207. The AUC for PF within the overall substrate map and co-localisation with the IZ was 0.67, and 0.73 within low voltage zones (<1.5mV). Conclusions PF mapping may identify critical components of the VT circuit during SR substrate mapping and its utilisation may compliment established substrate mapping approaches. PF guided ablation strategies require further evaluation in future prospective studies.

Improving functional substrate delineation for ablation of ventricular tachycardia using high-density electroanatomic mapping and double ventricular extra stimuli protocol

Abstract Background A partial delineation of targets for ventricular tachycardia (VT) ablation may contribute to a suboptimal success rate. Abnormal electrograms (EGMs) with low-voltage near-field components might be concealed within high-amplitude far-field signals. Our hypothesis posited that acquiring functional mapping after double ventricular extrastimuli (S3 protocol) could reveal relevant areas of functional substrate overlooked during sinus or S1 mapping. Purpose To assess the benefit and feasibility of functional substrate mapping using a full ventricle S3 protocol and to evaluate its colocalization with conducting channels (CCs) identified in late gadolinium enhancement cardiac magnetic resonance (LGE-CMR). Methods (Figure 1) - An S3 mapping protocol with a drive train of S1 followed by S2 (effective refractory period (ERP) +30ms) and S3 (ERP+50ms) from the RV apex was conducted in 40 consecutive patients undergoing scar-related VT ablation. Deceleration zones (DZs) and areas of late potentials (LPs) were identified for all maps (S1, S2, and S3). Pre-procedural non-invasive substrate assessment was performed with LGE-CMR and post-processing using a commercially available system with automated CC identification. Results The S3 protocol was completed in 34 of the 40 procedures (85.0%). Repeated induction of ventricular arrhythmias prevented the full S3 protocol in 5 patients (15.0%). Functional substrate identified during S3 activation mapping was significantly more extensive than that identified using S2 and S1, including a higher number of DZs (2.94, 2.47, and 1.82, respectively; p<0.01) and a wider area of LPs (44.1cm2, 38.2cm2, and 29.4cm2, respectively; p<0.001). The percentage of CCs unmasked by DZs and LPs using S3 maps was significantly higher than the ones using S2 and S1 maps(78%, 65%, and 48%; p<0.001, and 88%, 81%, and 68%; p<0.01, repectively). After VT ablation based on an S3 protocol, 77.9% of patients have been VT free during a median follow-up of 13.6 months. Conclusions (Graphical abstract -Figure 2) - This novel substrate-based protocol for assessing functional substrate is feasible in most patients, enables better identification of ablation targets, and has the potential to improve patient prognosis post-ablation.Methods - The S3 protocolConclusion - Graphical abstract

Preprocedural substrate assessment with computed tomography as an adjunct to endocardial voltage mapping for ablation of ventricular tachycardia: feasibility, procedural data and outcomes

Abstract Background Catheter ablation is an established therapy for ventricular tachycardia (VT) with endocardial voltage map (EVM) being the standard tool to characterize proarrhythmic substrate. However, this method is limited in certain ways, especially as intramural or epicardial substrate is not detected. In this context, multi-detector computed tomography (MDCT) has emerged as a promising alternative to cardiac MRI for preprocedural substrate assessment. Purpose Data regarding MDCT- guided VT ablation is scarce, especially in the context of late iodine enhancement MDCT. Present study sought to assess procedural parameters, safety, and efficacy of MDCT-guided VT ablation in direct comparison with a conventional VT ablation approach and is, to the best of our knowledge, the first systematic evaluation of clinical routine use of MDCT for preprocedural substrate assessment. Methods All patients (pts) undergoing VT ablation between January 2022 and August 2023 were included in this single-center registry. For MDCT-guided VT the CT images were uploaded to an online platform and processed using a dedicated software. Procedural parameters of MDCT-guided procedures were compared with the conventional EVM approach, and the study endpoint was a composite of death from any cause, heart failure hospitalization, and recurrence of VT. Results A total of 70 consecutive pts (age 62±13 y, 83% male) was included, of those 27/70 pts (39%) undergoing MDCT-guided and 43/70 pts (61 %) conventional VT ablation. An additional EVM was acquired in all MDCT pts. Baseline characteristics were similar. At comparable procedure durations (MDCT: 217±74 min, EVM: 194±57 min, p=0.15) the MDCT group showed a trend towards shorter mapping times (MDCT: 42±18 min, EVM: 49±13 min, p=0.09), particularly in cases with non-ischemic cardiomyopathy (NICM) (MDCT: 41±20 min, EVM: 54±15 min, p=0.07). An epicardial access was obtained in 8/23 pts (30 %) in the MDCT group and in 6/47 pts (14 %) in the EVM group (p=0.13). Bipolar ablation due to intramural scar detected by MDCT was performed in 3/27 pts (11 %) and in none in the EVM group. There was no difference in manifestation of acute kidney injury (MDCT: 3/17 pts (18 %) vs. EVM: 4/24 pts (21 %), p=1.0). After a median follow-up of 116 days (IQR 80-260 days), the study endpoint occurred in 8/17 (47 %) pts after MDCT-guided and in 14/31 pts (45 %) after conventional VT ablation. In one patient in the MDCT group a relevant coronary artery stenosis with urgent revascularization occurred immediately after bipolar ablation at the LV summit. No other complications were observed. Conclusion MDCT-guided VT ablation is safe and feasible with no differences in contrast agent-induced kidney injuries. Preprocedural CT substrate assessment identified complex intramural and epicardial scar, leading to bipolar and epicardial ablation. Mapping times trended shorter in the MDCT group, particularly in non-ischemic cardiomyopathy cases.

Impact of functional gene groups on outcomes after ablation of ventricular tachycardia in patients with inherited left ventricular cardiomyopathy: an international multicentre study

Abstract Background Advances in genetic testing has enabled identification of pathogenic variants of different functional gene groups associated with non-dilated left ventricular cardiomyopathy (NDLCM)/dilated cardiomyopathy (DCM) and ventricular tachycardia (VT). However, there is limited data on the impact of functional groups on VT ablation outcome. Aim We aimed to assess the impact of likely pathogenic/pathogenic variants (LP/Pv) of different functional gene groups on heart failure (HF) outcomes and VT recurrence in patients with NDLCM/DCM after VT ablation. Methods Patients with NDLCM/DCM who underwent genetic testing (next-generation sequencing) and were referred for VT ablation were enrolled at 6 participating centers. Patients were followed for VT recurrence, HF-related adverse outcomes (death, left ventricular assist device [LVAD], or heart transplantation due to HF), and all-cause mortality. Results A total of 239 patients (age 55±14yrs; male n=193; LVEF 40±12%; amiodarone at admission n=103; ICD n=180) were included. LP/Pv were identified in 128 patients (54%), predominantly found in genes encoding sarcomeric (n=36/128, [28%]; titin n=20, myosin binding protein C n=12), followed by nuclear membrane (n=27/128, [22%]; lamin A/C; n=26), desmosomal (n=23/128, [18%]; desmoplakin n=11, plakophilin n=9), cytoskeleton (n=12/128, [9%]; filamin C n=8), and sarcoplasmic reticulum proteins (n=12/128, [9%]; phospholamban n=10). Variants of unknown significance (n=32) were grouped with patients who tested negative. Acute complete ablation success, defined as non-VT inducibility of any sustained monomorphic VT, was achieved in 113 patients (47%), 63 (56%) with LP/Pv. During a median follow-up of 32 months, 108 patients (45%) had VT recurrence, 41 (17%) had HF-related adverse outcomes (death with/without LVAD in 34, LVAD in 2, heart transplantation in 5) and 47 (20%) died. Patients with LP/Pv were more likely to have VT recurrence, HF-related adverse outcomes and had a higher mortality compared to those without (VT, 68 [53%] vs. 40 [36%]; HF-related adverse outcomes, 30 [23%] vs. 11 [10%]; mortality, 30 [23%] vs. 17 [15%]; log-rank, P<0.01 for all). As compared to patients without LP/Pv, those with LP/Pv in genes encoding nuclear membrane or sarcomeric proteins had significantly worse (P<0.01 for both) and those with LP/Pv in genes encoding desmosomal proteins had similar HF and VT recurrence outcomes (Figure). Of interest, patients with LP/Pv in genes encoding cytoskeleton proteins had favorable HF-related adverse outcomes, but worse VT recurrence (P=0.02) compared to those without LP/Pv (Figure). Conclusion In patients with NDLCM/DCM and VT, the impact of LP/Pv on HF and VT-recurrence outcomes after ablation differs across functional groups. Integrating genetic testing in the comprehensive evaluation of patients with NDLCM/DCM undergoing VT ablation may facilitate personalized ablation strategies and early consideration of alternative HF treatments.

Long-term outcomes of ventricular tachycardia ablation in patients with ischemic and non-ischemic cardiomyopathy: a propensity-score matched analysis

Abstract Background Catheter ablation (CA) has been shown to be effective in the treatment of ventricular tachycardia (VT). Although some observational data suggest that patients with non-ischemic cardiomyopathy (NCIM) have less favorable clinical outcomes when compared to those with an ischemic etiology (ICM), direct comparisons are scarcely reported. We aimed to compare the outcomes of VT ablation in a propensity score-matched population of ICM or NICM patients. Methods Single-center observational registry including 246 consecutive patients with ischemic (ICM, N=166) and non-ischemic cardiomyopathy (NICM, N=80) who underwent drug-resistant VT ablation from 2012 to 2023. A propensity score (PS) was used to match patients in a 1:1 fashion according to the following variables: age, sex, left ventricular ejection fraction (LVEF), NYHA class, electrical storm (ES) at presentation, and previous endocardial VT ablation. The outcomes of interest were VT-free survival and all-cause mortality. Results The PS yielded two groups of 71 patients each (mean age 63±10 years, 92.3% male, mean LVEF 35±10%, 35.9% with ES at presentation, and 23.2% with previous ablation), well matched for baseline characteristics. Those with NICM were more likely to undergo epicardial or combined VT ablation (43.7% vs. 9.9%, P<0.001). The procedural complication rate was low (4.9%, N=7) and similar between groups (P>0.05). During a median follow-up of 27 (IQR 15–45) months, patients with NICM had a significantly lower VT-free survival (53.5% vs. 69.0%, log-rank P=0.037), although there were no differences regarding all-cause mortality (22.5% vs. 16.9%, log-rank P=0.245) – Figure. Multivariate analysis identified NICM (HR 2.34 [95% CI 1.32–4.14], P=0.004), NYHA class III/ IV (HR 2.11 [95% CI 1.11–4.04], P=0.024), and chronic kidney disease (HR 2.23 [95% CI 1.25–3.96], P=0.006), as independent predictors of VT recurrence. Non-inducibility of any VT immediately after ablation was associated with significantly lower rates of VT recurrence (22.8%/ year vs. 42.4%/ year, log-rank P=0.03). Conclusion NCIM patients are at increased risk of VT recurrence after ablation, although long-term mortality was similar to ICM in a propensity-matched cohort. Non-inducibility of any VT after CA is associated with better outcomes.Figure

Epicardial catheter ablation of ventricular tachycardia in patients of acm - from a university hospital report in switzerland

Abstract Background Arrhythmogenic left ventricular cardiomyopathy (ALVC) as a subtype of arrhythmogenic cardiomyopathy (ACM) is increasingly being recognized. Cardiac magnetic resonance (CMR) has emerged as the primary imaging modality for the diagnosis of ACM. In patients with right-dominant ACM (ARVC) and recurrent sustained ventricular tachycardia (VT), endocardial +/-epicardial ablation yields good clinical outcomes in the long-term. However, studies on VT ablation in ACM with LV involvement are scarce. Purpose We sought to investigate clinical outcomes of VT ablation in ACM patients with LV involvement. Methods The study included patients from the Zurich ACM Registry who met 2020 "Padua Criteria" for ACM and underwent VT ablation between January 2018 and July 2023. Epicardial ablation was performed in patients with recurrent sustained VT despite endocardial ablation, those lacking and endocardial substrate or if the ECG of the VT / substrate on CMR was suggestive of an epicardial origin. Catheter ablation was guided by activation/entrainment mapping for mappable VT, and pace mapping/voltage mapping during sinus rhythm for unmappable VT. Consecutive follow-up of all patients was performed according to our protocol. Results Twenty-one ACM patients underwent n=24 VT ablation procedures. Of those 20 patients, 6 patients (30%) had LV involvement on CMR. Eight (33%) patients underwent epicardial +/- endocardial ablation. Among patients receiving epicardial ablation, 3 patients (38%) had LV involvement. These three underwent a single ablation procedure, which was epicardial only. Total follow-up was 30 months (range 4-43). Three-month sustained VT/VF recurrence rates were 12% in the ACM group with LV involvement vs 25% in ACM without LV involvement. All patients with sustained VT/VF recurrence underwent repeat ablation via an epicardial approach within 3 months and were free of sustained VT/VF thereafter during a median follow-up of 12 months. One-year recurrence rate did not differ between ACM patients with LV involvement vs. without LV involvement (7.7% vs 8.3%, P＝0.117). Seven out of eight epicardial ablations achieved freedom from VT/VF after one-year follow-up. One ARVC patient with previous endocardial ablation had recurrent VT one month after epicardial ablation, which was free of VT after Flecainide combined with beta-blocker. No significant differences were found in the use of beta-blockers and antiarrhythmic drugs between both groups (ACM with LV involvement vs. without LV involvement) at baseline and during one-year follow-up. Conclusions Single or adjuvant epicardial substrate ablation of VT in arrhythmogenic cardiomyopathy is promising in terms of postprocedural VT free survival, especially in patients with left ventricular involvement demonstrated by CMR.Figure 1Figure 2

Digital health in the electrophysiological lab: Initial experience, safety and feasibility using remote support for arrhythmia ablation-Results of REMOTE-VA study

Abstract Background In most electrophysiology (EP) labs, electroanatomical mapping (EAM) systems are operated on site by qualified staff or field technical engineers (FTE). Due to lack of skilled personnel, the FTE usually must travel between different hospitals and procedures must be planned in advance. Ablation of ventricular arrhythmias (VA) represents the most complex procedure in the field. The use of remote support (RS) to guide complex EP procedures has the potential to increase flexibility, reduce travel times and maximise healthcare resources. Purpose To evaluate the safety and feasibility of RS as compared to on-site support guided catheter ablation procedures for VA. Methods All patients undergoing ventricular tachycardia (VT) or premature ventricular complex (PVC) ablation using remote support were included. The electronical system of the hospital was searched for 30 days postprocedural emergency department (ED) visits, unplanned ambulatory presentations, and readmissions. RS guided three-dimensional (3D) mapping was achieved by connecting the EAM software with an integrated audio-visual solution for remote support. Internet connection-based headphones and high-resolution cameras ensured the communication between the operator and the FTE, who worked exclusively from home office. The control group consisted of an equal number of patients matched for the type of procedure and undergoing on-site guided procedures. All ablations were performed using high density 3D mapping, as per institutional standard. Results Between October 2022 and October 2023, a total of 25 patients underwent VT (32%) or PVC ablation in our centre using RS and were compared to 25 patients undergoing the same procedures under on-site guidance. In the RS group one patient underwent epicardial VT ablation and another one bipolar ablation for VT Storm. The demographic data were similar between the groups. The median procedure time was 120 (93, 143) minutes in the RS group and 112 (95, 138) minutes in the control group (p=0.95), while the fluoroscopy time was 11.4 (7.0, 14.0) and 7.26 (5.0, 10.9) minutes respectively (p=0.08). The procedural success was achieved in 96% procedures in the RS group and in 100% in the control group. No technical issues or changes to on-site support were reported. One minor intraprocedural complication was noted among the control patients, while 24% of the patients in each group developed minor complications until discharge. Two patients in the RS group and one in the control group had ED visits, while only one patient in the control group had an unplanned ambulatory presentation. One unplanned readmission was reported in the control group (Table 1). Conclusions Even in the most complex procedures including epicardial ablation, the use of RS was feasible and safe in this single centre study. This approach has the potential to increase the feasibility in case of emergency procedures, reduce travel times, and maximise healthcare resources.

Characterization of ventricular tachycardia ablation in end-stage heart failure patients with left ventricular assist device (CHANNELED-Registry)

Abstract Background Left-ventricular-assist-devices (LVAD) are an established therapy for patients with end-stage heart failure. These patients are at high risk for ventricular tachycardia (VT) and ICD-shocks due to the arrhythmogenic substrate of the underlying cardiomyopathy itself and as the LVAD cannula might be arrhythmogenic, too. Purpose Data on catheter ablation of VT in LVAD patients are scarce and current evidence predominantly consists of case reports and small single-center series. This multicenter registry seeks to systematically assess the mechanism and origin of VA in LVAD patients and to evaluate procedural parameters and outcome of VT ablation in this special subset of patients. Methods Retrospective data of LVAD patients referred for VT ablation at 11 tertiary care centers between January 2017 and August 2023 were included in this multicenter registry. VT mechanisms, procedural data, clinical follow-up, and outcome were assessed. Results We report 49 patients (88% male, age 61±8 years) undergoing 51 ablation procedures included in this ongoing registry. The underlying cardiomyopathy was ischemic in 25/49 patients (51%) and nonischemic in 24/49 patients (49%) with a mean left ventricular ejection fraction of 21%±6% before LVAD implantation. Most catheter ablations were conducted after prior antiarrhythmic drug (AAD) treatment (15/51 on amiodarone, 13/51 on prior intensification of amiodarone treatment, 18/51 on prior combination of two or more AADs). A total of 75 VTs were targeted (39/51 transseptal, 3/51 retrograde aortic, 9/51 combined approaches) and 13/49 patients required VT ablation less than 1 month after LVAD implantation. Of the targeted VTs the majority (69%) were cardiomyopathy related and only 31% of the targeted VTs were related to the LVAD cannula. In 5/51 procedures access site complications and in 1/51 procedures a pericardial effusion occurred; one patient showed a post procedural oxygen desaturation; despite immediate intubation the patient deceased from hypoxic brain injury. No LVAD related complications were observed. A follow-up was available for 35/49 patients. During a median follow-up of 277 days (IQR 78-625 days), 5/35 patients were transplanted and 13/35 died. Patients died after a median time of 124 days (IQR 34-952 days) primarily from heart failure, sepsis, or intracranial bleeding. Of the remaining 17/35 patients, 7/17 patients were arrhythmia-free at a median follow-up of 212 days (IQR 78-639 days). Conclusion Although often chosen as last resort, catheter ablation of VT in LVAD patients is feasible and can be performed safely in this critically ill subset of heart failure patients in experienced centers. Intrinsic myocardial scar seems to be the dominant substrate in these patients but LVAD cannulae contribute to a significant number of VTs. In the presence of severely reduced LV function the VT recurrence remains high despite maximal therapy and prognosis of these patients is limited.

Non-invasive assessment of the ventricular tachycardia isthmus during sinus rhythm

Abstract Background The ablation of ventricular tachycardias (VT) presents significant challenges due to the complex and time-consuming approaches involved in identifying arrhythmogenic regions. Combining non-invasive electrocardiographic imaging (ECGI) with endocardial mapping could potentially enhance the efficacy of interventions. Objective To evaluate the capability of ECGI in guiding operators towards areas of VT isthmuses during sinus rhythm. Methods Patients with scar-related VT, confirmed by late gadolinium enhancement cardiac magnetic resonance, were prospectively enrolled. We compared the areas of slowed conduction identified by ECGI with the VT sustaining regions identified endocardially. Simultaneous Electroanatomical Mapping (EAM) and ECGI mapping were performed during VT ablation procedures. In patients in whom a hemodynamically stable VT was maintained, the reentry circuit was mapped endocardially, and the ablation target was identified. The left ventricle was segmented into 9 regions, categorized as either VT-isthmus or non-VT isthmus based on EAM findings. Prior to ablation, local activation times (LAT) and conduction velocity (CV) ECGI sinus maps were computed. Slow conduction was quantified non-invasively by computing different ECGI metrics per region, including the mean and the standard deviation (SD) of LAT and CV, the regional Total Activation Time (rTAT) – time span between the earliest and latest activated nodes–, and the Slow Conduction Velocity (SCV) – the percentage of nodes where velocity falls below 60 cm/s -. Results The study included 20 consecutive patients with ischemic cardiomyopathy who were referred for VT ablation. A total of 21 regions linked to the VT isthmus were identified endocardially in 17 patients (age: 66.1±8.8 years, 94.1% male, left ventricular ejection fraction: 26.4±7.3%). Figure 1 illustrates the correlation between the VT circuit and the ECGI sinus map in two patients with extensive left ventricular fibrosis. ECGI metrics related to VT isthmuses exhibited a higher standard deviation in both LAT (18.1±2.0 vs 9.8±1.2 ms; p=0.001), and CV (50.4±4.7 vs 37.1±2.8 cm/s; p=0.011), and a greater percentage of nodes with slowed conduction (13.7±2.7 vs 7.4±1.6 %; p=0.029), compared to non-VT isthmus regions, Figure 2. Multivariate logistic regression analysis revealed that SD-LAT was the strongest predictor of VT isthmus localization. Conclusion ECGI has demonstrated the capability to pinpoint slowed conduction areas responsible for VT in sinus rhythm, showing promise in planning and guiding VT ablation strategies. This advancement paves the way for further research into using this non-invasive tool to improve risk stratification methods for ventricular arrhythmias.

Manifestation of conduction block zones by substrate mapping evaluated under multidirectional pacing during ventricular tachycardia ablation

Abstract Introduction Catheter ablation (CA) has proven to be effective therapy for ventricular tachycardia (VT) in patients with structural heart disease. However, activation mapping during VT is often limited in case of non-inducible, non-sustained or hemodynamically tolerable. It has been reported that a substrate-based approach for identifying conduction block and slow-conducting sites during sinus rhythm and ventricular pacing is promising strategies for CA. However, detailed analysis on the effectiveness of substrate mapping with multidirectional pacing to identify critical isthmus in unmappable VT have been lacking. Purpose The purpose of the present study was to evaluate the effectiveness of substrate mapping with multidirectional pacing in VT ablation. Methods From April 2022 to July 2023, 7 consecutive patients (4 men, age 62±9years) who underwent CA of VTs at our institute were enrolled. Isochronal late activation mapping (ILAM) was performed during sinus rhythm, right ventricular (RV) and left ventricular (LV) pacing. Cardiovascular magnetic resonance were performed in 3 of 7 cases to assess the distribution of myocardial late gadolinium enhancement. For catheter ablation, 2Fr electrode catheter was inserted into the anterior interventricular vein (AIV) at the distal site of the coronary sinus. LV pacing was performed using an electrode catheter placed in the AIV. ILAM were constructed by annotating the last deflection of each electrogram. Results In the 7 patients, 5 had ischemic cardiomyopathy and 2 had non-ischemic cardiomyopathy (Figure 1). During sinus rhythm, a deceleration zone (DZ) was identified in only 1 of 7 cases, consistent with linear conduction block. RV pacing demonstrated DZ in 3 of 7 cases. LV pacing revealed DZ in 6 of 7 cases, all of which had conduction blocks. U-shaped conduction blocks, which was not detectable in activation mapping during sinus rhythm, was newly identified in 29% of RV pacing, 71% of LV pacing. Combined RV and LV pacing unmasked the U-shaped conduction block in 86% of the cases. Only in case 7, activation mapping of VT with a cycle length of 470ms could be performed, and VT isthmus activation was observed in the area surrounded by the U-shaped conduction block (Figure 2). In other cases, the clinical VTs were unmappable because of the hemodynamic instability with tachycardia cycle length of approximately 300 milliseconds. Eventually, VTs became non-inducible in 3 of 5 cases in which induction was performed after the CA. During the follow-up period of 7±5 months, 6 of 7 cases remained free from any VT episodes. One patient showed small amount of pericardial effusion after CA. However, there were no life-threatening complications in any patients. Conclusion Substrate mapping using several different wavefront vectors in unstable VTs unveiled conduction block zones that might be potential ablation target sites for VT.Figure 1Figure 2

Dynamic voltage mapping of the ventricular tachycardia substrate

Abstract Background Substrate mapping techniques that predict ventricular tachycardia (VT) isthmus components in sinus or paced rhythm are necessary as mapping during VT is often not possible. Voltage maps lack accuracy in differentiating scar, traditionally displayed as tissue <0.50mV, from bordering arrhythmogenic substrate. We developed a practical technique aiming to improve the utility of a voltage map during VT ablation, termed ‘Dynamic Voltage Mapping’ (DVM). Methods Consecutive patients with post-infarct VT at our centre underwent left ventricle (LV) voltage mapping (mean 4762 points) with Carto3 v.7® and a PentaRay®, or Ensite X® and a HD Grid mapping catheter. Both mapping systems offer algorithms that allow substrate activation maps to be superimposed and analysed on the surface of a voltage display (i.e. Carto Ripple Maps, or Ensite X activation vectors). DVM is a process that sequentially adjusts the voltage display to highlight scar tissue in areas devoid of Ripple bars, or in areas where activation vectors point in multiple unfathomable directions (‘vector disarray’). This approach is summarised in Figures 1 & 2 and was retrospectively performed in all cases. This alternative scar voltage limit was termed the ‘DVM scar threshold’ (mV). Tissue below this threshold was termed ‘DVM-scar’, and tissue immediately surrounding (up to 0.5mV) was termed "DVM-Borderzone (BZ)". Results Twenty-five patients (mean age 64.4±11.0 years, 88% male, LV ejection fraction 31.8±6.9%, 16.4±8.5 years since infarct) were studied (n=15 Carto; n=10 EnSite). Across all cases, the mean shell area with voltage <0.50 mV was 36.8±20.3 cm2. The mean DVM scar threshold was 0.24±0.07 mV (Carto: 0.22±0.07 mV [range 0.12–0.35 mV]; EnSite: 0.26±0.08 [range 0.18–0.50 mV]). The mean DVM-scar area was 18.4±14.3 cm2, significantly smaller than the traditional 0.50mV value (p=0.0002). In the 8 patients where stable VT was mapped, the VT isthmus sites co-located within the DVM-BZ in all cases, exemplified in the figures. Pace-mapping at the DVM-BZ matched the remaining unmappable VT morphologies. Ablation lesions were retrospectively superimposed onto the DVM map and generally co-located within the DVM-BZ. No ablation was delivered in tissues >0.5mV. At median follow-up of 8.8 months, VT burden significantly reduced (median 3 episodes in 3-months pre vs. 0 post; p<0.001), with 76% of patients VT-free. Conclusion DVM appears to improve the delineation of the post-infarct VT substrate, and is feasible using two commercially-available mapping systems. The mean voltage threshold that differentiated DVM-Scar from BZ tissue was significantly lower than the traditional 0.50 mV scar definition, at 0.24mV, though ranged widely, suggesting that scar thresholds require individualised substrate definition. Targeted ablation of DVM-BZ may be effective at reducing future VT, though requires prospective validation.Figure 1Figure 2

Ablation of hemodynamically unstable ventricular tachycardia guided by ultra-high density pacemapping and PASO correlation map, a multi-center clinical trial

Abstract Background Due to hemodynamic instability during ventricular tachycardia (VT), obtaining a complete electroanatomic map is often difficult if not impossible. Pace-mapping has progressed but still lacks precision and may not reveal sufficient details for complete ablation of the potential critical isthmus. Purpose We hypothesized that a novel strategy of combining ultra-high density (HD) pace-mapping using the PASO algorithm and Carto system to match the induced/clinical VT may aid in the reconstruction of the VT critical isthmus and effective VT ablation leading to reduce the risks of VT recurrence. Methods This was a prospective, multi-center trial conducted between January 2021 and July 2023. We enrolled 30 patients with ischemic heart disease and scar mediated recurrent VT clinically indicated for ablation. Following induction of clinical VT, we performed ultra-HD pace-mapping (5-10 mm distance between pacing points) of the identified ventricular substrate. Using PASO Module, a pacing correlation map (PCM) was constructed based on the percentage match to the induced VT. Using the PCM and the measured stimulation to electrogram intervals, the potential VT critical isthmus was reconstructed. Radiofrequency ablation was carried out to completely transect the delineated isthmus. Post ablation, repeat HD mapping and ablation was performed, until the PASO % correlation dropped from >93% to <70%, indicating at least uni-directional (orthodromic to the perceived VT circuit) conduction block through the ablation line. Follow-up data, including ICD interrogations were collected via chart review. Outcomes were compared to 60 propensity-score matched patients with an ICD who were enrolled in the Ranolazine in High-Risk Patients with Implanted Cardioverter-Defibrillators (RAID) trial who did not undergo VT ablation and served as the control group. The primary endpoint was the first occurrence of any VT at 1-year of follow-up. Results Patients enrolled had a mean age of 69 ± 9 years and 13% were women. Propensity matched patients from the RAID trial had similar baseline clinical characteristics to patients who underwent VT ablation (Table). At 1 year follow up, there was a significantly lower cumulative probability of VT/VF recurrent events in the patients who underwent PCM guided ablation as compared with the control group (17% vs 69%, respectively; log-rank p<0.001 Figure). There were no serious procedure related complications with all patients remaining free of adverse events or death at 30 days. Conclusion Our findings suggest that ablation for unstable or unmappable VT is enhanced by ultra-high density pace-mapping to reconstruct the potential VT circuit and is associated with a significantly lower rate of recurrent VT as compared with patients managed with aggressive and escalating medical therapy.Cumulative probability of ICD therapyBaseline clinical characteristics

Catheter ablation of papillary muscle arrhythmias: procedural characteristics and long term outcome

Abstract Background Ventricular arrhythmias (VA) originating from the papillary muscles can occur both in patients with and without structural heart disease. Although catheter ablation is the treatment of choice, ablation success remains challenging and long-term outcomes for this origin of VA are still unsatisfactory. Methods and Results All patients undergoing catheter ablation for premature ventricular contractions or ventricular tachycardia between june 2009 and november 2022 were analyzed. 66 patients (26 female (39%), mean age 60±15 years) undergoing catheter ablation of VA originating from the papillary muscle were identified. 21/66 (32%) patients had a reduced or mildly reduced left ventricular ejection fraction at time of initial presentation. While mitral valve regurgitation was present in 32/66 (48%) patients, mitral valve prolapse was observed in only 2/66 (3%) patients. 6/66 (9%) patients presented with non-sustained ventricular tachycardia (VT) and 1/66 (2%) patient presented with sustainend VT prior to catheter ablation. 61/66 (92%) patients underwent ablation of PVCs of the left ventricular papillary muscles (22/66 (33%) patients anterolateral; 39 (59%) patients posteromedial). 5/66 patients underwent ablation of premature ventricular complex (PVC) originating from the papillary muscles of the right ventricle. In 13/66 (19.7%) patients only a retrograde approach was used, in 26/66 (39.5%) patients a retrograde and an additional transeptal approach and in only 10/66 (15.2%) patients solely a transeptal approach. Mean PVC QRS duration was 152.5 ± 3.5 msec. Ablation was acutely successful in 44/66 (67%) patients. Mean procedure time was 145.8 ± 63.7 minutes and mean number of radiofrequency applications was 21.3 ± 16.7 (25 to 55 Watts, 37764.2 ± 27824.1 Joules). Overall, procedural complications occurred in 4/66 (6%) patients Follow up data were obtained from Holter ECGs, review of medical records, patient consultation, or via structured follow-up within the prospective TRUST registry. All information was combined to assess recurrence of PVC/VT. Recurrence of VA originating from the papillary muscles occurred in 11/66 (17%) patients. 9/66 patients (14%) underwent re-ablation due to recurrence of VA originating from the papillary muscles after previous ablation procedures. Conclusion Catheter ablation of papillary muscle arrhythmias is associated with a single procedural success rate of 67% with a procedural complication rate of 6%. 14% of patients underwent re-ablation due to recurrence of papillary muscle arrhythmias.

Long-term outcome after catheter ablation for fascicular ventricular tachycardia in a single high-volume center in Germany

Abstract Background Idiopathic Fascicular Ventricular Tachycardia (IFVT) accounts for less than 10% of all VTs and represents the most common idiopathic ventricular tachycardia of the left ventricle. This study reports on clinical and procedural characteristics and the long-term outcome of patients undergoing catheter ablation of premature ventricular complexes (PVC) and ventricular tachycardias (VTs) arising in proximity of the left ventricular conduction system. Methods and results This study includes 27 patients (17 male, 45 ± 17 years; 10 females, 50 ± 11 years) who underwent electrophysiological examinations at a tertiary ablation center over a period of 14 years (2009 to 2022). Follow-up was performed via regular Holter-ECGs and clinical evaluations, or via structured follow-up within the prospective TRUST registry. In 21/27 patients (77.8%), the left posterior fascicle (LPF) was involved in the IFVT. In 4 (14.8%) the left anterior fascicle (LAF) was involved and in 2 (7.4%) patients an origin in the upper septal (US) area was demonstrated. 22/27 (81.5%) patients had a preserved left ventricular ejection fraction (LVEF) and only 5 (18.5%) patients had a LVEF less than 50% at the time of presentation. 14/27 (51.9%) patients presented with PVC or non-sustained VTs with the following distribution: 10 (71.4%) originating from the LPF, 3 (21.4%) from the LAF and 1 (7.1%) from the US. 21/27 (77.8%) patients presented with sustained VTs: 16 (76.2%) arising from the LPF, 4 (19%) from the LAF and 1 (4.8%) from the US. However, only 2 (7.4%) patients presented in sustained VT at the beginning of the EP procedure. In 16 (59.3%) patients a sustained VT was induced during the EP study via isoprenaline and/or programmed ventricular stimulation. Mean QRS duration of the VT was 124.5 ± 14.6 msec. In 21 (77.7%) patients only a retrograde approach was used, in 3 (11.1%) patients a retrograde and an additional transeptal approach and in only 3 (11.1%) patients solely a transeptal approach. Mean number of radiofrequency applications was 11.8 ± 12.6 (30 to 40 Watts, 27545.6 ± 30524.4 Joules). FVT ablation was acutely successful in 24 patients (88.9%). In 2 patients (7.4%) no ablation was performed due to inability to induce VT under sedation. 3/27 patients (11.1%) underwent re-ablation due to FVT recurrence after previous ablation procedures. Moreover, 3 (11.1%) additional patients underwent repeated VT ablations during follow-up, but the arrhythmia originated from a different LV area. No procedure-related complication occurred. In 4 patients (14.8%) left fascicular posterior block was caused by ablation and in 3 (11.1%) patients a complete left bundle block. Mean procedure time was 130 ± 48.9 minutes. Conclusion Ablation of FVT in a tertiary ablation center is associated with a high single procedural success rate of 88.9% during long-term follow-up, with a mild risk of fascicular injury. 11.1% of patients underwent re-ablation due to FVT recurrence.

Coronary venous ethanol ablation of refractory left ventricular summit arrhythmias: comparison with radiofrequency ablation

Abstract Background Radiofrequency (RF) ablation of ventricular premature beats (VPBs) and ventricular tachycardia (VT) arising from the left ventricular (LV) summit is challenging and may fail due to anatomical inaccessibility of the substrate. Coronary Venous Ethanol Ablation (CVEA) has been suggested as a bailout strategy following failed RF ablation of LV Summit Arrhythmias (LVSA). Comparison with RF ablation strategies are lacking. Purpose To compare CVEA with RF ablation for the treatment of LVSA. Methods Between January and November 2023, 20 patients were treated with CVEA for LVSA. Results were compared to 36 patients that underwent RF ablation for LVSA (Panel A). Endo- and/or epicardial RF ablation was performed based on local signal precocity and pace-mapping. Coronary venogram-guided mapping of coronary sinus side-branches was performed using an angioplasty wire connected to our EP-recording system using a crocodile clamp. The target veins were specifically selected based on early presystolic potentials and confirmed by matching VPB pace-maps. For the treatment, angioplasty balloon(s) measuring 2-2.5×6-8 mm were employed to administer ethanol into the target branch of the coronary sinus. Data are reported as mean ± standard deviation, unless otherwise indicated. P-values are two-tailed. Results (Panel B): Patient characteristics were similar for both groups, except for the number of prior failed ablation procedures (75% males; mean age: 63 ± 13 y; 31 with structural heart disease; mean LVEF 39 ± 9%; VPB burden 25 ± 12%; Number of (NS)VT 72 ± 151; 65% redo in case of CVEA, 28% for RF). Mean pace-match was 97 ± 1% (99.8% max.) for CVEA versus 93 ± 8% (97% max.) for RF ablation (P = 0.002). Earliest presystolic signal was -70 ms (-49 ± 12) for CVEA versus -50 ms (-31 ± 12) for RF (P = 0.0002). Acute success, defined as elimination of VPB/VT was 95% versus 83% for CVEA and RF ablation respectively. VPB burden at Holter was 1 ± 3% 6-8 weeks after CVEA versus 8 ± 10% following RF ablation (P = 0.024). In patients with VT, number of (NS)VT decreased by 90% after CVEA (P = 0.014), while this was not significant for RF ablation. After a median follow-up of 8 months (IQR 2-10), 15% of CVEA patients showed residual non-LV summit ventricular arrhythmia as compared to 39% showing recurrence of LV summit VPB or VT following RF ablation. No patients died. One patient developed tamponade following RF ablation and one patient received PCI in the CVEA group. Conclusion Retrograde coronary venous ethanol ablation is an effective ablation strategy for the treatment of LV summit arrhythmias, also compared to conventional RF ablation.

Termination without global capture: electrocardiographic and anatomical characteristics using 3D-electroanatomical mapping system in reentrant ventricular tachycardia

Abstract Background Termination without global capture (TWGC) is the phenomenon which a pacing stimulus applied during ventricular tachycardia (VT) terminates the tachycardia without generating a QRS complex, and is considered as an indicator for the critical component of the circuit. The details of the electrocardiographic and anatomical characteristics of the site using a 3D-electroanatomical mapping system (3D-EAM) remain unknown. Purpose This study aimed to retrospectively analyze the cases that showed TWGC during VT mapping and ablation, and to investigate the electrocardiographic characteristics and relationship with the substrate identified by 3D-EAM. Methods Of 632 cases of VT associated with structural heart disease from July, 2019 to July, 2023 at a university hospital and a university medical center, cases with TWGC were analyzed. Results TWGC was observed in 10 patients (median age 61 years, 9 males, 5 ischemic cardiomyopathy, median LVEF 31%) at least once (12 times) in 11 locations. Local capture was observed in 6. The QRS morphology generated by continued pacing after TWGC matched the clinical VT in only 5 VTs (42%). Five showed decremental conduction of stimulus to QRS interval following the TWGC. In 11 locations, 4 corresponded to scar area (<0.1 mV) in the voltage map, 6 to border zone (0.1-1.5 mV), and 1 had no information on 3D-EAM. Of 12 times of TWGC, 3 were at the entrance, 1 at the central isthmus, and 1 at the exit. Acute elimination of clinical VT was successful in 7 of 10. Conclusions More than half of the sites with TWGC were located at the border zone in 3D-EAM. TWGC also occurred in the central or exit area, and local capture was observed frequently.Termination without global capture

Modification of deceleration zones and late potentials after ventricular tachycardias substrate ablation

Abstract Introduction Characterization of ventricular substrate is crucial during ventricular tachycardias (VT) ablation. Isochronal Late Activation Mapping (ILAM) is a recently introduced visualization tool that permit to identify areas of slow conduction (deceleration zones, DZs), these seems to well correlate with VT isthmuses. However, there are limited data about changes in this substrate after catheter ablations. Purpose To evaluate changes that occur to DZs and late potentials (LPs) after repeated ablative lesion sets. Methods High density voltage map and ILAM of the left ventricles (LV) during paced rhythm were performed in all cases. LV activation map was divided into 8 isochrones and DZ was defined as the presence of 3 isochrones within 1 cm-radius. LPs were defined as EGMs with late and fragmented components after the QRS. PES was performed at the beginning and at the end of the procedure. Each RF lesion set were applied with force-sensing irrigation catheter (target LSI 6-6.5) to abolish all the DZs and LPs discovered at baseline. After the first lesion set a re-map was performed looking for persistent DZs or LPs in the same LV segment (residual) or the appearance in a new ones (shift) in a 17-segment LV model; additional RF lesions and maps were performed only if DZs or LPs were still present in the last map. Results Of 28 VT cases considered, 9 patients with detailed LV maps and subsequent remaps were analyzed. Median age was 66 yo, 8 males, 7/9 with ischemic heart disease. In 7/9 patients clinical VTs were also induced and mapped. At baseline ILAM maps identified 24 DZs; after the first lesion set, 9 DZs were still appreciable at the same localization and 9 shifts to another LV segment (e.g. fig1). In 100% of patients at least one DZ was still appreciable at the first remap, while in 78% of patients a shift of the previous one was noted. At remap after a second lesion set 9 DZs were still present (3 residual, 6 shifts) in 33% of pts. Finally after a third lesion set only 2 DZs were still present in the same segment and then abolished. Furthermore, at baseline LPs were present in 28 LV segments, and after the first lesion set LPs were still present in 15 segments (9 residual, 6 new LPs). At first remap 78% of patients still showed LPs. After a second lesion set LPs were still visible in 6 segments (3 residual, 3 shift) in 22% of patients. In the third remap only in 2 segments could still be appreciated (1 residual, 1 shift) and finally were all abolished (summary in fig2). In 5/7 patients the clinical VT isthmus were identified in a DZ at baseline. At median FU of 6 months 7/9 patients has no VT recurrences, while there was one non-cardiovascular death. Conclusions Frequently DZs and LPs persistence is observed after first sets of lesions and additional RF deliveries are required for complete abolition. Remapping often demonstrates that both DZs and LPs move to other adjacent LV segments, likely where they were previously masked.Fig1Fig2